Elected State Court Judges in the United States

The April 10 Economist included a brief article noting the issues regarding elected state court judges, and its text is set out below as a fair use. According to the article, some or all of the judges are elected in 39 of the United States.This topic has been debated for years, but little has changed except that more and more money is being spent on judicial elections. The article has specifics on the latter.


I would add three observations to the debate; the first one comes from the judge I clerked for, Howard C. Ryan, who was an elected state court judge. His point was a pragmatic one, which is that reformers need to be flexible in their proposed solutions and cannot expect to hit a "home run" on the first try. For example, the "reform" solution that works for the hundreds or thousands of judges in Cook County, Illinois probably will not work for a "downstate" Illinois county with only a handful of judges and perhaps only dozens of lawyers. Why? Because some reform proposals aimed at Cook County called for panels of X lawyers, with X being a small number in Cook County but an unattainable number in some farming counties with modest numbers of lawyers and judges. (During my clerkship way back in 1983, the issue was somewhat "hot" in Illinois and so Judge Ryan, as a "downstate" judge, explained to us some of the very real differences between Cook County courts and the courts in the rest of the state. In my opinion, he's absolutely correct that one size does not fit all. The Judge, by the way, also was open-minded. Indeed, to further the analysis, he asked me to research and present him with a memo summarizing how various nations around the world create their judiciary.)


Second, there is in my view much merit to ensuring that many of our appellate judges have spent meaningful time as trial judges. Trial courts are dynamic places with things said and unsaid because of the exigencies of the moment and many other factors. When an appellate court gathers to decide cases, it is I think important that there are some judges in the room who have a feel for the what is really "harmless error," and the pressures of long trial days. This is not to suggest creating a black letter rule requiring trial court experience - I join with those who say that it would be a grave mistake to exclude all academics, nor do we want to exclude the lawyers who never worked as judges but spent years trying cases, and so know the nature of trials.


Third, there is the question of why the topic has produced so little substantive debate (as opposed to sound bites and posturing), and so little meaningful change. On this topic, I commend to all Robert Reich's newest book: Supercapitalism. It's an insightful look at where we as a nation are today in terms of the political process. It's also refreshing to read a book with lots of facts, footnotes to the sources, and an absence of spin.


_____________________________________________________________
Torts and courts

Apr 10th 2008 MADISON, WISCONSIN
From The Economist print edition
Life, liberty and the pursuit of a fair judiciary


JUSTICE is meant to be impartial. To this end, Britain's judges are appointed for life. In America federal judges are as well. But in 39 states some or all judges must face election and re-election, often with unbecoming hoopla. An election to the Supreme Court of the state of Wisconsin has just involved about $5.5m and more than 12,000 aired advertisements. Habeas circus, one might say.


Michael Gableman defeated Louis Butler, an incumbent on Wisconsin's Supreme Court, on April 1st, and the cacophony has not yet subsided. The scuffle has revealed two worrying traits of America's judicial elections.

First, they have become bitter contests. In 2006 91% of Supreme Court elections featured television advertisements, up from 22% in 2000, according to New York University's Brennan Centre. Second, the war over tort, or liability, reform has turned judicial elections into a nasty battlefield--especially in those states where state Supreme Court justices are directly elected. Karl Rove, once George Bush's Svengali, ascended in part by helping Texas businessmen fight trial lawyers for control of that state's highest court. The most expensive judicial race in America's history, a $9.3m fight in 2004, saw tort interests pour money into rival campaigns for a seat on the Illinois Supreme Court.
In Wisconsin the signs are troubling. The state's new era of judicial elections began last year. A series of rulings had galvanised corporate leaders, explains James Buchen of Wisconsin Manufacturers and Commerce (WMC), the state's business lobby. In one ruling in 2005, the Supreme Court overturned the state's caps on medical-malpractice cases. In another, the court ruled that a plaintiff could sue several manufacturers when he did not know which (if any) had caused him injury.
In 2007 groups from all sides poured cash into a state Supreme Court race, spending $5.8m. In this month's election one estimate is that the candidates together raised about $1m (Mr Butler outspent Mr Gableman), while outside groups such as WMC and the teachers' union spent more than $4.5m.
This year's flood of money might have drawn less censure if it had spurred a proper debate on judicial philosophy. It didn't. Mr Gableman's campaign produced an advertisement suggesting that Mr Butler, a black man, had helped free a black rapist. An advertisement supporting Mr Butler claimed that Mr Gableman was soft on paedophiles. Even WMC's advertisements were about crime. Regardless of the tenor of the campaign, money may be undermining faith in the court. A recent poll conducted for Justice at Stake, a group devoted to judicial independence, found that 78% of respondents in Wisconsin believe campaign contributions influence judges' rulings.
The question is whether to change the new dispensation and, if so, how? Comprehensive legal reform might help keep the tort war from seeping into judicial elections. But the elections themselves are unlikely to be scrapped. More feasible would be to pass reforms, such as public financing for campaigns or stricter rules to prevent conflicts of interest. In Wisconsin politicians and Supreme Court judges all work beneath the state capitol's giant dome. It is getting hard to tell the difference between them. "

Attorneys' Fee Awards in Mass Tort Litigation

Some recent attorneys' fees awards illustrate that specialized mass tort litigation is becoming ever more entrepreneurial and rewarding when claims succeed in areas such as product liability litigation. Much of the history of teh financing of contingent fee claims is very well explained by Professor Stephen C. Yeazell of UCLA in his 2001 article, "Re-Financing Civil Litigation," 51 DePaul Law Review 183 (2001). I highly recommend the article to anyone interested in understanding the economics of mass tort litigation. The article was part of a DePaul Law School symposium organized through a $ 1 million gift from Robert Clifford, one of Chicago's most-respected plaintiff's lawyers. One might also consider Prof. Yeazell's related online lecture apparently published as an honor by UCLA for distinguished work by its professors.

The recent examples? "Fen-phen" litigation produced a most recent award of $ 412 million fee award for several plaintiff's firms. The Point of Law authors note that all of the awards work out to about $1,000 per hour based on hours reported to have been billed. The Mass Tort Litigation blog authors also noted the award and provide cites for some of the key rulings in that litigation.

The Florida phase of the tobacco litigation recently produced a $ 218 million fee award for plaintiff's counsel. The award is described as providing a 5x multiplier for the risks undertaken by plaintiff's counsel, Stanley and Susan Rosenblatt. According to the news article, the trial judge who awarded the fees took pains to praise the efforts of plaintiff's counsel, saying:

''I think this is one shining example of an effort that was undertaken with diligence and for an amount of time that would have destroyed most people,'' Miller said, according to a hearing transcript. The Rosenblatts' performance is ``an example of the kind of lawyering that is done here in South Florida.''

The Dickie Scruggs Saga - a/k/a Crisis Management for State Farm

The Dickie Scruggs saga has been much hyped. Indeed, one could say it is over-hyped because although there are some lawyers who appear to have bent or broken the rules, there are many more who act ethically and do a great job for their clients.

In any event, the best summary I've seen of the Dickie Scruggs saga is by Roger Parloff of Fortune. An upcoming issue of Fortune will have a condensed article, but an extended online version is available here. In addition, Mr. Parloff's blog has further information.

W.R. Grace Asbestos Bankruptcy Settlement - WSJ Editorial

"Mass tort" and Chapter 11 are words that have frequently been used together since Johns-Manville filed for bankruptcy back in 1982. Now, as of April 7, there has been a settlement in principle of many but not all of the asbestos issues remaining in the W.R. Grace asbestos bankruptcy. The "spinners" are all hard at work on characterizing the settlement, and I'm reading with interest to see what others have to say. For now, I'm simply going to note some of the spins and add some small comments.

An April 12, 2008 WSJ editorial merits mention as they declare the settlement a good deal for Grace, with Grace said to have paid $ 2.5 billion on a $ 6 billion demand. More than the numbers, the WSJ praises Grace for having blazed a legal trail:

"By making a solid legal case that bankruptcy courts have an obligation to delve into the legitimacy of tort claims, W.R. Grace has provided a road map to other companies that want to fight dubious suits. The company has also sent a message to the plaintiffs bar that it should expect its handiwork to be examined more closely in future bankruptcy cases."

In my opinion, the praise for trail-blazing is accurate, and the WSJ's kind words are well deserved by Grace's inside and outside lawyers, not to mention management in general.

Mass Tort Claims - Do Shrinking Jobs and Insurance Benefits Increase Propensity to Claim ?

Recent news has been full of stories about rapid general inflation around the world, especially increased food costs leading to protests (and worse) around the globe. Today's news also include an article from the NYT that details soaring co-payment expenses in the US. For a tort lawyer, these articles bring to mind an ongoing tort litigation issue: the propensity to file tort claims.

The tort litigation world includes much argument and posturing regarding propensity to claim. The debate about claiming is made somewhat useless when the two sides cite extreme examples of fraud, which can be either inarguably fraudulent claiming or inarguably fraudulent corporate conduct. What it would be good to see is a meaningful article looking at the propensity to claim as a function of micro economic events, such as manufacturing plant closings, or as a function of the elimination or reduction of medical benefits by a company, especially for retirees. One also wonders of there is meaningful correlation between claiming and macro numbers for inflation of unemployment. Please speak up if you know of any research on these points - I've not seen any.

Until there is research, I'll rely on my personal observation that it seems plain that prospective plaintiffs are often-created when a business closes a plant, completely terminates its retiree medical insurance plans, or insurance benefits are materially reduced. Indeed, when manufacturing plants close, some plaintiff's firms sometimes target the former plant workers as potential plaintiffs, and medical screenings may follow if the plant included use of "toxins." Simply put, otherwise proud and independent retirees who have significant medical issues sometimes say "off the record" that tort litigation is the only means they know of to try to create cash flow sufficient to cover medical expenses. Thus, corporations and governments sometimes may actually be "the cause" behind increased tort claiming. Thinking globally, one would think that global tort claiming will increase as economic changes are harder and harder on the middle class and on those persons already at the bottom of the economic ladder.


Implications of New Research on Asbestos as a "Cause" of "Disease"

An online article published April 10, 2008 in ScienceNOW provides an overview of detailed research published in Science indicating that asbestos fibers stimulate production of a form of interleukin (IL-1β), which promotes inflammation. I've not yet read the article and so cannot say whether the article addresses asbestos fibers in the generic sense or if it distingushes between fiber types.

The article and commenters quoted in it suggest there will be future efforts to determine whether anti-inflammatory drugs can limit the biologic processes (disease, one might say), and that it may in the future become possible to test for increased levels of the implicated form of interleukin. (Wikipedia offers a nice article on interleukin, including striking color illustrations.)

So, how is this article relevant to asbestos litgation in particular and tort litigation in general? For asbestos litigation, the relevance is that scientific discoveries of this sort may lead to new tests that asbestos claimants could use to try to recover for increased future risk of contracting "disease," or for the defense side to try to use to show that a particular person person is not at "meaningful" risk of suffering from a "disease" deemed appropriate for compensation.

The research also may make its way into the factual proofs that have historically been part of the legal rationales for the "triple trigger" rationale for defining the "injuries" that courts decide are sufficient to "trigger" traditional CGL insurance coverage that was often but not always purchased by manufacturing firms prior to the advent of the so-called "asbestos exclusion" that became fairly common around 1985. The U.S. law on insurance coverage for asbestos claims is quite developed, but insurance coverage remains a wide open topic in many countries where asbestos litigation is just starting to take shape. And, depending on the scope and results of this and future research, it may add new grist for arguments about the "chrysotile defense" and/or whether a "low dose" exposure actually plays a legally meaningful role in the onset of what we define as "disease."

For tort litigation in general, this is an illustration of the type of issues that courts and lawyers will have to confront as science pushes forward at ever increasing speed. Over the coming years, it seems inevitable that courts and lawyers will spend increasing amounts of time thinking about how "disease" occurs on a biologic basis, and what can be done to prevent a biologic process from resulting in a tumor that actually causes "physical impairment." The answers may have a profound impact on the scope of new and old legal rationales for tort law claims (e.g. fear of cancer claims), and on the scope of recoverable damages.

Legislative and regulatory bodies also will have opportunties to consider and apply new science, and might even come to sensible conclusions to avoid the "wastes" inherent in litigation. But we've gone for decades without much sensible action from federal U.S. legislators, and the states have taken various approaches, mainly but not always after the federal legislators failed to act. It remains to be seen how legislators and regulators will respond in other nations. Legislative and regulatory actions related to asbestos are picking up speed outside the US, but that topic must wait for another day.

____________________________
Set out below is an excerpt from the ScienceNOW article as to the biologic process investigated:

"Tschopp and colleagues exposed to asbestos human and mouse immune cells that lurk in the lungs. They found that the material stimulated an inflammasome called Nalp3 to release interleukin-1β (IL-1β), a chemical that incites inflammation. But the real proof came from mice that were bred to lack Nalp3. When these mice were exposed to asbestos for 9 days, they produced lower levels of IL-1β and less lung inflammation than did mice with Nalp3, confirming that the inflammasome is key to triggering at least some of the negative effects of the fiber, the researchers report online today in Science. Tschopp speculates that because asbestos fibers lodge in the body, prolonged exposure causes chronic inflammation that over time could result in lung scarring and cancer. The details still need to be worked out, but the researchers note that IL-1β has been linked to other cancers."

Japanese Company Voluntarily Pays Asbestos Claimant

I'm often told that asbestos litigation is essentially just a U.S. issue because our culture is said to be so litigious. However, even the reputedly nonlitigious Japanese culture has produced asbestos claims and payments. A Japanese website reports that a Japanese corporation recently voluntarily paid compensation to a person claiming to suffer from mesothelioma. The claimant was aided by a victim's rights group based in Japan. The victim worked at a manufacturing plant reported to have used crocidolite fibers.

Science, Cancer and Law - New Studies Link Genes and Lung Cancer

Science moves much faster than does "the law," and the changes in science over time will have a profound impact on the framing and resolution of legal issues.

For a new example, consider that respected medical journals Nature and Nature Genetics this month published articles from three research teams asserting identification of one or more genes they say are materially related to an increased risk of contracting non- small cell lung cancer, which comprises about 80% of lung cancers. Having one copy of the gene is said to be a characteristic of about 50% for persons of European descent, and far lower among persons from Asia and Africa. According to the authors, inheriting one copy of the gene raises the risk by about 28%, and inheriting two copies of the gene raises the risk by 70-80%. Some of the authors suggest the gene may be tied to the tendency to smoke. The press articles indicate that the research teams made the usual prediction that tests for the two genes will be available in the future.

The implications for law in general are profound when one considers all of the societal and legal issues related to health itself, and the obligations of insurers, governments or individuals for the expenses of treating (or, some day, preventing) a non small cell tumor in the lung. Those many issues are far beyond the scope of this blog. Here, the focus will remain on the potential tort litigation issues that may flow from these studies, and the other studies that surely will follow.

For example, many asbestos claimants with "lung cancer" attibute the disease in whole or in part to inhalation of asbestos fibers and/or cigarette smoking. In such cases, what difference should it or does it make if the claimant has one or more copies of the identified genes, and has the non small cell tumor? Defendants may ask for genetic testing and if they find the presence of one or two copies of the gene said to be relevant, they may argue that their presence breaks the legal causation chain and so precludes liability. Defense counsel also may invoke Daubert principles and seek to bar expert testimony from plaintiff's experts if the testimony is not focused in persons with two copies of the gene - will that tactic be allowed to work ? How soon?

Plaintiffs' counsel, on the other hand, may be expected to argue that the "two copies" claimant is just like the "eggshell skull" plaintiff we all heard about in law school. We were taught that the general rule is that a liable defendant cannot avoid financial responsibility simply because a particular person had an especially thin skull. Will that rule continue in force in the age of genomic testing? Should it stay in force as is, or does it need modification?

Plaintiffs also may use the presence of two copies of the gene to try to meet legal standards they cannot meet today for some claimants advancing fear of cancer claims or other claims. For example, some state law opinions (e.g Havner in Texas) will for the most part refuse to permit a claim unless the plaintiff proves that there is a relative risk of a specific disease created by "exposure" to a substance that is at or exceeds 2.0. Will science over time allow plaintiffs' lawyers to meet the 2.0 standard for claimants with the "two copies" even if the 2.0 standard could not be met for a person without the two copies of the "lung cancer" gene?

These and many other issues are arriving fast. For press articles with more details on the lung cancer studies, see:

http://news.bbc.co.uk/2/hi/health/7325971.stm; http://www.latimes.com/features/health/medicine/la-sci-lung3apr03,1,483181.story

What's in a Name - Why GlobalTort ?

Why GlobalTort? From the lawyer's perspective, the name was chosen for multiple reasons.

One reason for the name GlobalTort is that it succinctly identifies the reality of most of today's mass tort litigation. Due to the globalization of manufacturing supply and distribution chains, and the information sharing power created by the Internet, "mass tort" litigation is rapidly evolving into a truly global industry that will expand and prosper until societies find new, consensus ways to reasonably balance the competing interests inherent in tort litigation. Globalization also means that plaintiff and defense firms are now starting to act in a truly global fashion, with offices and affiliates around the world. "Mass tort" claims also are now being drawn from and/or filed in a wide range of nations.

The GlobalTort name also was chosen because each group of so-called "mass tort" cases almost invariably raises addtional issues that cross a variety of lines. For example, all or most of the cases within a particular group of cases likely will include issues that plaintiff's lawyers like to say are "global" issues (e.g. when did "the ____ industry know ____.") In addtion, the underlying cases should not be looked at in a vacuum, and instead they raise a wide range of issues that include disclosure obligations, financial accounting rules, issues regarding indemnification rights and obligations, and insurance coverage issues, including issues regarding "shared insurance," meaning historic insurance available to multiple members of corporate families.

The name also was chosen because our three founders practice in divergent substantive areas, and so we hope to identify and offer comments on a wider than usual range of the of the private and public issues related to tort litigtion. In addition, we intend to go beyond just the cases and to comment on notable legislation, regulation and policy issues. And, finally, we hope the blog will over time evolve to the point that it includes comments from other nations and other professionals, thus furthering a global view of tort litigation.